Molecular Profiling Of The Immunoglobulin Proteome In Primary Sjögren’s Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$322,460.00
Summary
Primary Sjögren’s syndrome is a common autoimmune disease. The patients have high levels of circulating immunoglobulins (Igs) in their blood-a hallmark of the disorder. The applicant proposes to sequence these Igs and identify their so-called variable region molecular signatures. These signatures can then be used in a mass spectrometric-based diagnostic platform to identify unique clones in patients as early markers of the disease process, and hopefully lead to more relevant diagnostic markers.
Personalised Medicine Markers Of Anti-EGFR Antibody Therapy In Metastatic Colorectal Cancer: Accelerating Clinical Translation With Collaborative Meta-analyses Based On Individual-participant Data
Funder
National Health and Medical Research Council
Funding Amount
$300,953.00
Summary
When selecting cancer therapy we take into account ‘biomarkers’, biological cancer characteristics that predict treatment success. We will work with an international group, the Advanced Colorectal Cancer Database, to analyse individual patient clinical trial data. We intend to validate biomarkers used to select treatment with cetuximab or panitumumab. Cancer genes called KRAS, NRAS, PTEN, PIK3CA, EREG and BRAF will be examined. Our study will provide best evidence for personalised treatment.
Assessment Of Novel Biomarkers That Are Related Neurobehavioural Dysfunction In Patients With Obstructive Sleep Anoea
Funder
National Health and Medical Research Council
Funding Amount
$312,941.00
Summary
Obstructive sleep apnea is recognised as a common condition that has a clearly measurable impact on public health. However it is often difficult for doctors to decide which patients have problems with driving or day to day brain functioning. This study will measure driving and memory during an extended period of waking in patients with sleep apnea. Special markers of brain function will be correlated with performance results during this extended wakefulness challenge.
Determining The Prerequisites For The Achievement Of Treatment-free Remission In Chronic Myeloid Leukaemia To Facilitate The Development Of New Therapeutic Approaches With Curative Intent
Funder
National Health and Medical Research Council
Funding Amount
$1,318,775.00
Summary
Chronic myeloid leukaemia (CML) can usually be treated effectively with long-term tyrosine kinase inhibitor (TKI) therapy. Remarkably, rare patients who achieve excellent responses can stop treatment altogether without relapsing. Detailed studies of these patients in terms of their genetic background, the biology of their leukaemia and their immune response may help us understand how this is possible, leading to new therapeutic approaches to make treatment-free remission more widely achievable.